EBS Q3 2017 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$430M

Q3 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$149M+4.6% YoY

Gross Profit

$83M55.7% margin

Operating Income

$48M32.0% margin

Net Income

$34M22.5% margin

EPS (Diluted)

$0.68

QoQ Revenue Growth

+48.3%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

$21M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$360M

Stockholders' Equity

$664M

Cash & Equivalents

$341M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$149M	$143M	+4.6%
Gross Profit	$83M	$76M	+9.2%
Operating Income	$48M	$35M	+34.6%
Net Income	$34M	$21M	+57.2%